Skip to content

Study · Non-randomized trial · n = 15 · 1995

9 results

Sandostatin LAR in acromegalic patients: a dose-range study.

Fløgstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, Jervell J

The Journal of clinical endocrinology and metabolism1 Dec 1995Cited by 45 (Europe PMC)

PMID8530606 (opens in a new tab)DOI10.1210/jcem.80.12.8530606 (opens in a new tab)PepBankPUB-08530606
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In active acromegaly, only 20 or 30 mg Sandostatin LAR suppressed basal GH to levels comparable to subcutaneous treatment.

    In plain wordsIn active acromegaly, only 20 or 30 mg Sandostatin LAR suppressed basal GH to levels comparable to subcutaneous octreotide.

    Peptide
    Octreotide
    Outcome
    DecreaseBasal GH suppression
    Study

    n = 15

    Comparator
    Subcutaneous octreotide treatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 or 30 mg · intramuscular · single doseAs given in this study (human).

    Source sentences

    Summary
    Only injections of 20 or 30 mg were followed by a suppression of basal GH and insulin-like growth factor I to levels comparable to those seen during sc treatment.
    1 context sentence
    Summary · context
    We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc.
  2. 02HumanNon-randomized trialEfficacy outcome

    In active acromegaly, only 20 or 30 mg Sandostatin LAR suppressed insulin-like growth factor I to levels comparable to subcutaneous treatment.

    In plain wordsIn active acromegaly, only 20 or 30 mg Sandostatin LAR suppressed IGF-I to levels comparable to subcutaneous octreotide.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF-I suppression
    Study

    n = 15

    Comparator
    Subcutaneous octreotide treatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 or 30 mg · intramuscular · single doseAs given in this study (human).

    Source sentences

    Summary
    Only injections of 20 or 30 mg were followed by a suppression of basal GH and insulin-like growth factor I to levels comparable to those seen during sc treatment.
    1 context sentence
    Summary · context
    We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc.
  3. 03HumanNon-randomized trialEfficacy outcome

    In active acromegaly, Sandostatin LAR 20 mg suppressed mean GH below 5 micrograms/L for 4 weeks.

    In plain wordsIn active acromegaly, Sandostatin LAR 20 mg suppressed mean GH below 5 micrograms/L for 4 weeks.

    Peptide
    Octreotide
    Outcome
    DecreaseDuration of GH suppression with 20 mg
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg · intramuscular · single doseAs given in this study (human).

    Measurements

    Mean GH during suppression
    < 5 micrograms/L
    20 mg group
    Duration of mean GH suppression below 5 micrograms/L
    4 weeks
    20 mg group

    Source sentences

    Summary
    The suppression of mean GH to less than 5 micrograms/L lasted for 4 weeks in the group receiving 20 mg and for at least 6 weeks in those given 30 mg Sandostatin LAR.
    1 context sentence
    Summary · context
    We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc.
  4. 04HumanNon-randomized trialEfficacy outcome

    In active acromegaly, Sandostatin LAR 30 mg suppressed mean GH below 5 micrograms/L for at least 6 weeks.

    In plain wordsIn active acromegaly, Sandostatin LAR 30 mg suppressed mean GH below 5 micrograms/L for at least 6 weeks.

    Peptide
    Octreotide
    Outcome
    DecreaseDuration of GH suppression with 30 mg
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    30 mg · intramuscular · single doseAs given in this study (human).

    Measurements

    Mean GH during suppression
    < 5 micrograms/L
    30 mg group
    Duration of mean GH suppression below 5 micrograms/L
    ≥ 6 weeks
    30 mg group

    Source sentences

    Summary
    The suppression of mean GH to less than 5 micrograms/L lasted for 4 weeks in the group receiving 20 mg and for at least 6 weeks in those given 30 mg Sandostatin LAR.
    1 context sentence
    Summary · context
    We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc.
  5. 05HumanNon-randomized trialPharmacokinetics

    In active acromegaly, the Sandostatin LAR pharmacokinetic profile fitted a biphasic drug release model.

    In plain wordsIn active acromegaly, Sandostatin LAR showed a drug release profile with two phases.

    Peptide
    Octreotide
    Outcome
    Not applicableBiphasic release profile
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intramuscular · single doseAs given in this study (human).

    Source sentences

    Summary
    The pharmacokinetic profile fitted a biphasic drug release model previously described for peptides in similar drug delivery systems.
    1 context sentence
    Summary · context
    We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc.
  6. 06HumanNon-randomized trialSafety outcome

    In active acromegaly, Sandostatin LAR tolerability was good.

    In plain wordsIn active acromegaly, Sandostatin LAR tolerability was good.

    Peptide
    Octreotide
    Outcome
    Not applicableTolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intramuscular · single doseAs given in this study (human).

    Source sentences

    Summary
    Tolerability was good.
    1 context sentence
    Summary · context
    We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc.
  7. 07HumanObservational studyPharmacokinetics

    In active acromegaly, serum octreotide concentrations correlated with the intramuscular dose of Sandostatin LAR.

    In plain wordsIn active acromegaly, serum octreotide concentrations were linked to the intramuscular Sandostatin LAR dose.

    Peptide
    Octreotide
    Outcome
    Direction not reportedSerum concentration association with dose
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intramuscular · single doseAs given in this study (human).

    Source sentences

    Summary
    Serum concentrations correlated with the im administered dose.
    1 context sentence
    Summary · context
    We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc.
  8. 08HumanObservational studyEfficacy outcome

    In active acromegaly, GH suppression occurred at serum octreotide concentrations exceeding approximately 600 ng/L.

    In plain wordsIn active acromegaly, GH suppression occurred when serum octreotide exceeded approximately 600 ng/L.

    Peptide
    Octreotide
    Outcome
    DecreaseGH suppression concentration threshold
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intramuscular · single doseAs given in this study (human).

    Measurements

    Serum octreotide concentration for GH suppression
    ≈ 600 ng/L
    concentrations exceeding approximately this value

    Source sentences

    Summary
    Suppression of GH and insulin-like growth factor I was achieved at serum octreotide concentrations exceeding approximately 600 ng/L.
    1 context sentence
    Summary · context
    We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc.
  9. 09HumanObservational studyEfficacy outcome

    In active acromegaly, insulin-like growth factor I suppression occurred at serum octreotide concentrations exceeding approximately 600 ng/L.

    In plain wordsIn active acromegaly, IGF-I suppression occurred when serum octreotide exceeded approximately 600 ng/L.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF-I suppression concentration threshold
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intramuscular · single doseAs given in this study (human).

    Measurements

    Serum octreotide concentration for IGF-I suppression
    ≈ 600 ng/L
    concentrations exceeding approximately this value

    Source sentences

    Summary
    Suppression of GH and insulin-like growth factor I was achieved at serum octreotide concentrations exceeding approximately 600 ng/L.
    1 context sentence
    Summary · context
    We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.